35 related articles for article (PubMed ID: 18411502)
1. Sunitinib: new drug. For some gastrointestinal stromal tumours.
Prescrire Int; 2007 Aug; 16(90):138-41. PubMed ID: 17724833
[TBL] [Abstract][Full Text] [Related]
2. Avastin saga reveals debate over clinical trial endpoints.
Sharma SP
J Natl Cancer Inst; 2012 Jun; 104(11):800-1. PubMed ID: 22673590
[No Abstract] [Full Text] [Related]
3. Off-label use of bevacizumab: advanced adenocarcinoma of the pancreas.
Technol Eval Cent Assess Program Exec Summ; 2009 Oct; 24(4):1-3. PubMed ID: 20183930
[No Abstract] [Full Text] [Related]
4. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
5. Off-label uses of bevacizumab: renal cell carcinoma and other miscellaneous non-colorectal cancer indications.
Technol Eval Cent Assess Program Exec Summ; 2006 Oct; 21(9):1-4. PubMed ID: 17061399
[No Abstract] [Full Text] [Related]
6. [An new generation of antineoplastic agents--targeted therapy in gastrointestinal tumors].
Lang A; Graeven U
Zentralbl Chir; 2009 Jun; 134(3):189-92. PubMed ID: 19544236
[No Abstract] [Full Text] [Related]
7. Objective responses in patients with malignant melanoma or renal cell cancer in early clinical studies do not predict regulatory approval.
Goffin J; Baral S; Tu D; Nomikos D; Seymour L
Clin Cancer Res; 2005 Aug; 11(16):5928-34. PubMed ID: 16115935
[TBL] [Abstract][Full Text] [Related]
8. The challenge of rational development of complex natural products as cancer therapeutics.
White J
J Natl Cancer Inst; 2010 Jun; 102(12):834-5. PubMed ID: 20505150
[No Abstract] [Full Text] [Related]
9. Talactoferrin alpha receives fast-track designation for the treatment of non-small cell lung cancer.
McBride D
ONS Connect; 2007 Jan; 22(1):14. PubMed ID: 17393636
[No Abstract] [Full Text] [Related]
10. Phase II oncology trials: let's be positive.
Ratain MJ
Clin Cancer Res; 2005 Aug; 11(16):5661-2. PubMed ID: 16115898
[No Abstract] [Full Text] [Related]
11. Sorafenib for the treatment of advanced renal cell carcinoma.
Kane RC; Farrell AT; Saber H; Tang S; Williams G; Jee JM; Liang C; Booth B; Chidambaram N; Morse D; Sridhara R; Garvey P; Justice R; Pazdur R
Clin Cancer Res; 2006 Dec; 12(24):7271-8. PubMed ID: 17189398
[TBL] [Abstract][Full Text] [Related]
12. The evolving role of histology in the treatment of non-small cell lung cancer.
Rana N; Khurshid H
Med Health R I; 2010 Oct; 93(10):317-9. PubMed ID: 21284271
[No Abstract] [Full Text] [Related]
13. FDA cancels approval for bevacizumab in advanced breast cancer.
Tanne JH
BMJ; 2011 Nov; 343():d7684. PubMed ID: 22121166
[No Abstract] [Full Text] [Related]
14. Pushing the envelope.
Nat Biotechnol; 2011 Aug; 29(8):669. PubMed ID: 21822220
[No Abstract] [Full Text] [Related]
15. Preparation and antibacterial activity of isatogens and related compounds.
Hooper M; Patterson DA; Wibberley DG
J Pharm Pharmacol; 1965 Nov; 17(11):734-41. PubMed ID: 4160418
[No Abstract] [Full Text] [Related]
16. Central Nervous System-Specific Outcomes of Phase 3 Randomized Clinical Trials in Patients With Advanced Breast Cancer, Lung Cancer, and Melanoma.
Corbett K; Sharma A; Pond GR; Brastianos PK; Das S; Sahgal A; Jerzak KJ
JAMA Oncol; 2021 Jul; 7(7):1062-1064. PubMed ID: 34014298
[TBL] [Abstract][Full Text] [Related]
17. Off-label uses of sorafenib and sunitinib.
Technol Eval Cent Assess Program Exec Summ; 2008 Feb; 22(11):1-4. PubMed ID: 18411502
[No Abstract] [Full Text] [Related]
18. Off-label uses of bevacizumab: breast and lung cancer indications.
Technol Eval Cent Assess Program Exec Summ; 2006 Oct; 21(8):1-4. PubMed ID: 17061398
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
